Program
silevertinib
Also written as “RVU120”, “silevertinib in combination with temozolomide” and “silevertinib (BDTX-1535) monotherapy”.
Its studies are mostly in Leukemia, Myeloid, Acute · Glioblastoma · Primary Myelofibrosis · Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ryvu Therapeutics | 52 open or running | phase 2since Sep 7, 2021 | Sep 7, 2021 | Dec 2026phase 2 · NCT06987058 |
| Black Diamond Therapeutics | 22 open or running | phase 2since Feb 15, 2022 | Feb 15, 2022 | Nov 2028phase 2 · NCT07326566 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 7, 2021First study: phase 2 study in RecurrenceNew to Ryvu TherapeuticsRyvu Therapeutics · NCT05052255 · 66 enrolled · Poland, Spain
- Feb 15, 2022Black Diamond Therapeutics's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Black Diamond TherapeuticsBlack Diamond Therapeutics · NCT05256290 · 200 enrolled · United States
- Dec 19, 2023Phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06191263 · 98 planned · France, Italy, Poland and more
- Jan 5, 2024Phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06268574 · 62 enrolled · France, Italy, Poland and more
- Apr 29, 2024Phase 2 study in Primary MyelofibrosisRyvu Therapeutics · NCT06397313 · 36 enrolled · Italy, Poland
- May 15, 2025Phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06987058 · 14 planned · France, Poland
- Jan 7, 2026Phase 2 study in GlioblastomaBlack Diamond Therapeutics · NCT07326566 · 162 planned · United States
Ahead
- Dec 2026Primary completion: phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06987058
- Aug 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06191263
- Nov 2028Primary completion: phase 2 study in GlioblastomaBlack Diamond Therapeutics · NCT07326566
TargetBeta
“An orally bioavailable, brain penetrating, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, ”NCIt, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| befotertinibrule | Betta Pharmaceuticals | phase 3 | 6 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07326566Glioblastoma · United States | 2 | Recruiting | Black Diamond Therapeutics | Nov 2028 | 162 |
| NCT06987058Leukemia, Myeloid, Acute · France, Poland | 2 | By invitation | Ryvu Therapeutics | Dec 2026 | 14 |
| NCT06397313Primary Myelofibrosis · Italy, Poland | 2 | Terminated | Ryvu Therapeutics | Jun 30, 2026 | 36 |
| NCT06268574Leukemia, Myeloid, Acute · France, Italy, Poland and more | 2 | Terminated | Ryvu Therapeutics | Jun 30, 2025 | 62 |
| NCT06191263Leukemia, Myeloid, Acute · France, Italy, Poland and more | 2 | Recruiting | Ryvu Therapeutics | Aug 2027 | 98 |
| NCT05256290Carcinoma, Non-Small-Cell Lung · United States | 2 | Active, not recruiting | Black Diamond Therapeutics | Nov 3, 2025 | 200 |
| NCT05052255Recurrence · Poland, Spain | 2 | Terminated | Ryvu Therapeutics | Oct 2, 2025 | 66 |
How it is read
Names in the registry
- “RVU120”, 5 entries
- “silevertinib in combination with temozolomide”, 1 entry
- “silevertinib (BDTX-1535) monotherapy”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 3 studies
- Glioblastoma, 1 study
- Primary Myelofibrosis, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.